Abstract：Objective To observe the clinical effect of herpes zoster (HZ) treated with topical Scorzonera Herpes Ointment. Methods Sixty patients with HZ who met the inclusion criteria and attended the No.988 Hospital of Logistic Support Forces of the Chinese People’s Liberation Army from September 2020 to October 2021 were selected and divided into treatment group and control group according to the random number table method, with 30 cases in each group. The treatment group was given topical Scorzonera Herpes Ointment and the control group was given topical Recombinant Human Interferon α2b Gel, while both were given oral acyclovir 0.4 g/time, 5 time/day. The efficacy was evaluated after 10 d of treatment, and were observed and compared the efficacy scores of comprehensive symptoms and signs and visual analogue scores (VAS) of pain in the two groups on days 3, 7, and 10 of HZ were observed and compared. The time of erythema reduction, cessation of blistering, crusting, and debridement were observed during the treatment in the two groups. The incidence of postherpetic neuralgia (PHN) was compared between the two groups at a month of treatment. Results The clinical efficacy of the treatment group was better than that of the control group, and the difference was statistically significant (P＜0.05). The differences were statistically significant when comparing the intergroup, time, and interaction effects of total HZ symptom and sign ratings between the two groups (P＜0.05). Among them, the total score of HZ symptoms and signs on day 3 was lower than that before treatment, the total score of HZ symptoms and signs on day 7 was lower than that before treatment and on day 3, while the total score of HZ symptoms and signs on day 10 was lower than that at other time points in both groups, and the differences were statistically significant (P＜0.05). Except before the treatment, the total score of HZ symptoms and signs in the treatment group at the same time point was lower than that in the control group, and the difference was statistically significant (P＜0.05). The erythema reduction time, blister stopping time, crusting time, and debridement time in the treatment group were shorter than those in the control group, and the differences were statistically significant (P＜0.05). There were a statistically significant differences between the two groups in terms of VAS scores between groups, time, and interaction (P＜0.05). In both groups, VAS scores on day 3 were lower than before treatment, VAS scores on day 7 were lower than before treatment and on day 3, and VAS scores on day 10 were lower than at other time points, with statistically significant differences (P＜0.05). Except before the treatment, the treatment group had lower VAS scores than the control group at the same time point, and the difference was statistically significant (P＜0.05). The incidence of PHN in the treatment group was lower than that in the control group, and the difference was statistically significant (P＜0.05). When comparing the incidence of adverse reactions between the two groups, and the difference was not statistically significant (P＞0.05). Conclusion The effect of topical treatment of HZ with opium herpes cream is remarkable, which can more effectively reduce skin lesions, shorten the course of disease and relieve pain. It is especially effective in the prevention of PHN, with no adverse reactions in clinical application, safe and effective, and worthy of clinical promotion.
京公网安备 11010502046598号